Folate Analogue Inhibitor Pralatrexate Cas 146464-95-1
folate analogue inhibitor Pralatrexate Cas 146464-95-1
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Pralatrexate |
Purity:98% min |
|
CAS NO:146464-95-1 |
Solubility:DMSO50 mg/mL (104.72 mM) |
|
Molecular Formula:C23H23N7O5 |
Package:Package according to customer requirements |
|
Molecular Weight:477.4730 |
Storage:Store at -20℃ |
Quality control
Remarks
Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death.
Related Prodcuts:
Fidaxomicin; Marbofloxacin; CP-466722; TTP 22; D-64131; M344; CHIR-124; Reversine; XL228; VE-822; RI-1; SRPIN340; XL888; Rigosertib; APY29; NMS-873; PF-03758309; Telatinib
References
-
[1] Marchi E, et al. Clin Cancer Res, 2010, 16(14), 3648-3658.
-
[2] Izbicka E, et al. Cancer Chemother Pharmacol, 2009, 64(5), 993-999.
-
[3] Molina JR, et al. IDrugs, 2008, 11(7), 508-521.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.